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Title: Support for non-prescribed Anabolic Androgenic Steroids users: A qualitative 
exploration of their needs
Abstract
Anabolic Androgenic Steroids (AAS) are used by the general population (particularly male 
gym users) for their anabolic effects (increased muscle mass). Few studies have sought AAS 
users’ views on what information and support they need. This study focuses on ideal support 
wanted by people who use AAS. Interviews were conducted with 23 self-declared adult AAS 
users. Using thematic analysis, six themes were identified aligned to support and information 
wanted by AAS users: (1) specific types of information wanted: managing risks, (2) 
mechanisms for communication of advice, (3) specific types of support wanted: medical and 
emotional, (4) stigmatisation of people who use AAS, (5) paying for support services, (6) 
legality of AAS use.
Integral to the support was that it should be considered within the context of use and identity. 
Support needs to be specific, targeted towards AAS users ensuring that balanced and 
evidenced-based advice is given. Sensitivity to AAS users’ perceptions of their drug-use and 
the stigma of being classified in the same sub-set as other illicit drug users is relevant to 
facilitating successful engagement. Furthermore, there is a need to consider the emotional 
issues surrounding AAS use and how to meet these needs. 
Keywords: Androgenic Anabolic Steroids (AAS); Image and Performance Enhancing Drugs 
(IPEDs); Support; Harm Minimisation; Testosterone Replacement Therapy; Information
Manuscript word count: 7775
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Introduction
Anabolic-Androgenic Steroids (AAS) are synthetic derivatives of testosterone that mimic 
male sex hormones, and are used to build muscle mass (Pope Jr. & Kanayama, 2012). A 
meta-analysis of AAS use indicates a global lifetime prevalence of 3.3% (men: 6.4%, 
women: 1.6%) (Sagoe, Molde, Andreassen, Torsheim, & Pallesen, 2014). The use of AAS 
has roots  in sports, however, in recent years they are increasingly used by the general 
population (particularly male gym users) for their anabolic effects (Bojsen-Møller & 
Christiansen, 2010; Nutt, 2012). The benefits of AAS use are increased muscle and strength 
(Kicman, 2008) with a wide range of motivations for use (Greenway & Price, 2018). There 
are also potentially physical and psychological side-effects including: testicular atrophy, liver 
toxicity, gynaecomastia, myocardial injuries, infertility, depression, aggression and anxiety 
(Pope Jr. & Kanayama, 2012). AAS users access a range of professional services including 
support from medical professionals, pharmacies, and Needle and Syringe Programmes 
(NSPs), but mainly rely on peers/online fora for advice  (Kimergård & McVeigh, 2014; 
Tighe, Dunn, McKay, & Piatkowski, 2017). The legal status of AAS use differs from country 
to country (Van de Ven, Mulrooney, & McVeigh, 2019). Much of the support in the UK, 
New Zealand and Australia comes through public health initiatives to combat blood borne 
viruses (BBVs) (Kimergård & McVeigh, 2014) and is prevention focussed (Bates et al., 
2019) with little such support in the USA. 
In the UK there has been a drive towards harm reduction support, which rather than focusing 
on abstinence, seeks to minimise the harmful effects of substance use (Karoll, 2010). Such an 
approach focuses on the consequences of choices, recognising abstinence as an ideal whilst 
accepting alternatives as reducing harm, and considering whether behaviours are beneficial or 
detrimental to users and the wider society (Karoll, 2010) and academics have seen that harm 
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reduction services include AAS users (McVeigh, Kimergård, Bates, Hope, & Ncube, 2016). 
However, AAS users can be wary of using such services, for a variety of reasons including 
stigma, more faith in the knowledge of experienced users (Glass et al., 2019; Harvey, Keen, 
Teijlingen, & Parrish, 2019), or not perceiving the service is for them, e.g. why go to a needle 
exchange if using only oral steroids (van de Ven, Zahnow, McVeigh, & Winstock, 2019)? 
Salina and colleagues (2019) argue that there is a need to review the public health response to 
AAS use and the potential associated harms. For a start, public health initiatives should utilise 
more innovative methods of dissemination via peer networks, or involve AAS users in the co-
production of harm minimisation messages and materials, (Bates, Tod, Leavey, & McVeigh, 
2018; Glass et al., 2019; Griffiths, Henshaw, McKay, & Dunn, 2016; Van de Ven et al., 
2019). The AAS users’ voice is often missing (Harvey et al., 2019) and it could be argued 
that a way to increase engagement would be, where possible, to merge what users want 
within the public health approach. Consequently, the aim of this qualitative study was to 
ascertain the types of support needed by people use non-prescribed AAS.
Method
We conducted an online questionnaire aimed at predominantly recreational AAS users. The 
survey used three sampling methods: convenience, self-selected (Patton, 2013; Rees, 2011) 
and snowball sampling (Shaghaghi, Bhopal, & Sheikh, 2011). Internet distribution can help 
reach hard-to-reach populations (Rodham & Gavin, 2006), but it makes geographically 
controlling the location of the respondents difficult. Options for support and information may 
be impacted by location, both in terms of laws and policies on provisions of service, but 
evidence suggests that AAS users spend a lot of time online, where they access and tap into 
knowledge from experienced users and share research and information (Andreasson & 
Johansson, 2016). Moreover, the focus is on ideal support AAS and so despite the different 
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laws and services in different countries, each interviewee can still offer something relevant. 
Consequently, it was decided not to exclude on the basis of nationality, but only age and AAS 
use. The first author contacted each person who had completed the questionnaire and who 
was willing to be interviewed about their in-depth experience of support (or lack thereof).
Interviews
Semi-structured interviews, covering several topics including: side-effects experienced,  
advice sought, and support wanted, were conducted (Darlington & Scott, 2002). Participants 
were adults (age 18+) who were currently using or used non-prescribed AAS in the last six 
months. Ethical Approval was gained from the Institutional Review Board and from the 
Addictions Services as required. 
A video interview was conducted with a current AAS user as a pilot (van Teijlingen & 
Hundley, 2001) as no changes were made as a result of this the pilot interview was included 
in the final dataset. A wide range of methods for undertaking the interview was offered to the 
participants, including via the internet  (Rodham & Gavin, 2006), and by telephone (Holt, 
2010). By offering a choice of method the researchers were hopeful that this would 
encourage this hard-to-reach population to participate as it allowed them control over the 
level of anonymity i.e. through the use of pseudonyms and typed answers. However, typed 
live chat interviews may not allow for the same level of questioning as the verbal interviews, 
as they are constrained by the medium of typing (Opdenakker, 2014) . Participants’ 
interviews lasted between 45 to 110 minutes. The interviews were transcribed (except for two 
done via live typed ‘chat’). Participants were offered the opportunity to review the 
transcripts. 
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Data analysis
Thematic Analysis was applied using NVivo (Braun & Clarke, 2012). The interview data 
were coded both deductive and inductive and a coding framework was developed. Three 
interviews were coded independently by the third author and a secondary coding framework 
was created to improve the reliability of coding (De Wever, Schellens, Valcke, & Van Keer, 
2006). The second author used the framework to code three different transcripts for quality 
assurance, and no revisions were made as a result of this procedure. To ensure the voice of 
the AAS user is at the fore, spelling, grammar and wording has not been changed in the ‘chat’ 
text or interviews. Moreover, direct quotes are accompanied by participants’ pseudonyms, 
age, and country. 
Findings
The study entailed in-depth semi-structured interviews with 23 self-declared AAS users. 
Participants were male, aged 20 – 53, with the majority being white, employed and having a 
college level or higher of education (Table 1), with 87% (20/23) describing themselves as 
straight/heterosexual. Six participants competed in weightlifting or bodybuilding, the rest 
were recreational users, and all bar one trained regularly at the gym. 
Table 1 near here 
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Figure 1 identifies six themes and a number of sub-themes on support and information 
wanted by AAS users.
Figure 1 near here
Theme 1: specific types of information wanted: managing risks
Theme one identifies the specific types of information wanted based on three sub-themes (see 
Figure 1). This theme was sub-titled ‘managing risks’ as interviewees acknowledged both 
risks and ways to mitigate for them:
We all know that what we do can damage us, but we're not going to stop. Instead, it 
would make more sense for people to be educated on how to lessen the side-effects 
and the damage. People will take them irrespective of whether the advice is there or 
not... Me being one of those people (Clinton,20,UK)
The advice on types of substances to use was considered important as many had strong 
feelings that some substances were more harmful than others. A good example of this was 
‘Trenbolone’ as many felt it had too many negative effects. Nine participants talked about the 
pros and cons of Trenbolone; pros being the dramatic muscle change effects, and the cons 
included night sweats, shortness of breath and behavioural changes, such as quick to enrage 
and loss of empathy:
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(Trenbolone) made me so indifferent about …my relationship with the people around 
me. It …was almost like a sense of arrogance that no one else really mattered around 
me. (Peter,24,UK)
Some had stopped using it as a result of severe side-effects, but this was not so easy for 
others:
that's why I like doing Tren (=Trenbolone) so much, because it, it just sucks 
everything down really well … I don't know if I'm gonna keep doing it because … it 
makes me, I'm not empathetic to stuff (Joel,34,USA)
The authors did not specially set out to investigate the impact of individual brands of AAS, 
however, as this substance was referenced numerous times with significant side-effects it 
might be useful for those working in the field and AAS users to read the quotes included 
(Supplemental material 1).
Participants wanted information on long-term effects, such information needed to be 
balanced, knowledgeable and evidenced-based:
where I could actually get some evidence-based advice on it, like from somebody who 
knows what they're talking about not some guy who used to be a heroin addict in the 
needle exchange. Cos, he clearly doesn't know about steroids... break that down and 
say, look what you take matters a hell of a lot when it comes to the side-effects you're 
…going to get and also the results that you're going to get from it (Peter,24,UK)
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Moreover, information needed to be backed up by evidence and academic studies were 
needed to provide this:
to be clinical trials and moderated usage of it under the supervision of a health 
professionals… we wouldn't have to rely on these forums and people using their own 
bodies to experiment (Paul,29,USA)
Theme 2:  mechanisms for the communication of advice
Several channels were suggest d as to how information on AAS should be communicated 
(Figure 2). 
Figure 2 near here
One participant suggested a YouTube channel sponsored by a health authority, but others 
raised concerned that such services were often prevention focussed. The confidence that 
many participants put in ‘broscience’; i.e. online advice from experienced users (‘brothers’) 
was pronounced and participants had a number of ways of identifying those who were to be 
trusted: 
I am very selective with who I get my information from and I'll make that decision on 
who I think is credible and based on you know are they referencing studies, have they 
got sort of testimonials of people that they've worked with, are they like an authority 
in that area (Peter,24,UK)
There was a call to consider this harm reduction message in a balanced way: 
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I live in the United States and they refuse to even admit that steroids will put on 
muscle mass (Paul,29,USA)
Without resulting to the use of scare tactics: 
…the federal government says a drug, ‘a joint is a pill, is a needle, is a grave’, and by 
saying that all drugs are equally harmful... that's the problem about, …being 
hysterical, is that you lose all credibility for a public health intervention, if your 
messages are informed by moralism as opposed to public health... take a scientific 
fact-based, evidence-based approach to these topics and take the moralism out of it 
(Hugo, 53,USA)
Moreover, there was a concern that information should be targeted at young people, as they 
are more vulnerable. For one participant this was the key motivation for taking part in the 
study:
I was actually ecstatic to participate ... you should see the amount of kids that scare 
me, that are just dumping all these hormones in their body and they don't give a crap 
about their health. So anything that'll, that'll help people understand …and possibly 
contribute to harm reduction I'm all about. (Lewis,37,USA)
Theme 3: types of support wanted
The third theme with associated sub-themes identified the specific types of practical support 
wanted: 
I. Medical & practical support 
a. Access to harm reduction items e.g. needles
b. Access to blood panel tests
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c. Able to give blood
d. Access to someone knowledgeable on AAS-related side-effects and refer
e. Treatment for side-effects
f. Support to stop using
g. Need for Testosterone Replacement Therapy (TRT)
II. Support for the emotional impact of AAS use
Theme 3 - Subtheme 1: medical & practical support 
When talking about AAS side-effects and support needed no-one expressed concern about 
BBVs. However, some, including US participants, wanted more access to NSPs but more for 
convenience than harm minimisation:
needle services would probably be a good thing, I don't think it is as necessary as 
someone that is using heroin or something like that …there is this sort of connotation 
all steroid users are sharing needles which is really not the case even in the medical 
literature. (Asi,28,USA)
One person was less concerned with obtaining free needles and more in having a place to 
easily dispose of needles safely:
during my first cycle they had sharps bins, but it was very convenient, I used to take 
them to the gym in a bag and drop them off, but not now (Del,35,UK) 
In the UK, NSPs offer this drop-off service but many felt a certain stigma attached NSPs:
it would be ideal if that was more available but …once I tried to ask for needles at a 
needle exchange …they thought I was on heroin… I just don't want to deal with the 
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system …I'd rather just go and pay for the needles rather than deal with that sort of... 
judgement. (Powel,34,UK)
Participants also referenced the need for some sort of service to test the quality of products, 
raising concerns about using safely and minimising risk. 
Most stated that getting blood panel tests done was important and ideally this would include 
an opportunity to discuss the results with medical professionals. Such support also potentially 
acting as a preventative measure: 
Somewhere you could get your bloods done and actually get someone to tell you what 
it means, what you need to do…I think it would put a lot of people off for definite if 
they realised, like your liver toxicity … kinda telling people, look this can have these 
effects in the long term. (Andrew,25,UK)
One participant argued that if heroin users had a right to free needles then AAS users had a 
right to blood tests for harm minimisation purposes: 
a government large scale public health problem because from a policy standpoint, 
…whether it's heroin users having a right to clean needles or …bodybuilders having a 
right to medical monitoring of their blood (Hugo,53,USA)
Three people expressed a desire to be able to give blood and felt there were more risks from 
doing this yourself:
taking steroids in general is not overly harmful when taken in the correct way but if 
you had something like trying to drain your own blood to bring health markers into 
range that's whenever harm really starts to happen (Asi,28,USA)
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And one participant’s solution raised a potential public health risk: 
to be on the safe side, I donate every few months just to reduce the haemoglobin and 
haematocrit. …obviously I have to lie on the form because they won’t take the blood if 
you have taken steroids. If there was a way … to give blood in an official way then 
that would be a good idea. (Del,35,UK)
Many would seek support from a medical professional, including specialists such as 
endocrinologists, and wanted substances prescribed to mitigate side-effects both whilst on 
cycle but also for Post Cycle Therapy (PCT). For others the concern was not stopping use but 
ways to safely reduce usage, continue to use safely long-term and be able to openly talk about 
issues with a doctor: 
I would like to talk to my doctor about this stuff and make sure, I just want to be safe. 
I don't want my liver, or my kidneys to get destroyed from these drugs. I wish there 
was a proper, there was a right steps medically [sic]. (Joel,34,USA)
However, participants were clear that professionals needed more specialist knowledge on 
AAS. This perceived lack of knowledge was seen as a barrier, even for participants who said 
they would be willing to seek professional help to stop:
GPs and whatnot are super busy anyway, but …somewhere to get stuff from …to help 
counteract stuff, like clomid …If the help was totally anonymous, and also very high 
in knowledge. This is not the case now. (Andrew,25,UK)
The anonymity was also important, as some had heard stories about AAS use recorded on 
medical records impacting on insurance policies and this was also a concern. 
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There was a request for medical professionals, particularly in the UK, to recognise the need 
for support for low testosterone, and many users cited TRT as a reason for continuing use. 
Often describing their frustration with the medical profession’s reliance on set ranges and not 
taking into account the psychological impact on the individual:  
I can’t stop everything that is not an option, because I have low testosterone 
naturally, I need to be taking something. I was hoping to do this with the NHS, 
…they’re really useless… if the NHS don’t want to help, I will have to buy that myself 
online, and take that possibly for the rest of my life (Del,35,UK)
Theme 3 - Subtheme 2: support for emotional impact of AAS use
Some participants felt there was a need to consider the wider emotional impact of using AAS, 
both in terms of reasons for starting use:
People go on steroids for the other reasons so these root causes should be treated 
first. (Powel,34,UK)
and the impact of the emotional side-effects experienced on and off-cycle.
The side-effects of PCT were often related to low mood and increased anxiety. There were 
mixed views on benefits of PCT with some identifying emotional side-effects of using 
substances to mitigate side-effects: 
…is PCT protocol … and I noticed that the clomid had an effect on me actually made 
me feel quite anxious and it made me feel quite depressed. (Peter,24,UK)
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and others choosing not to use PCT but instead drop to a lower continual dose to avoid the 
emotional side-effects:  
either people are going to use them and go through what is called PCT…or what you 
can do is TRT and have times when you're going to use more and that is the choice 
that I made because it's generally healthier choice and because you don't go through 
these huge swings. (Johan,36,Hong Kong (French))
However, thoughts were different when it came to mitigate emotional side-effects when on-
cycle, in relation to those around increased irritation and anger. The predominant message 
was that AAS users were responsible for recognising and managing these themselves. 
Meditation was referenced by one participant as a useful tool to help with this:
I am quite self-aware you see I meditate every day. So, I notice things about myself 
very, very easily. So, I'll notice that my patience is a little bit more thin.  
(Peter/UK/24)
In terms of types of support, participants recommended a need for specialised counselling, 
and suggested: education, managing side-effects, dedicated phone lines, psychotherapy, 
someone to talk to, cognitive-behavioural therapy, and peer support groups. 
In terms of overall access to information and support, one participant advocated for specialist 
centres:
specialist clinics which offer a confidential service are a must when it comes to 
steroid users. The clinics that I have noticed that operate very well do three things. 
First of all, they are staffed by highly knowledgeable people who know the effect that 
steroids have on the body so they're very quick to identify which side-effects may very 
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well be steroid related and where referrals are appropriate. They offer full panel 
hormone blood tests which, again, are very useful at identifying potential problems 
and they are also run by non-judgmental people who are very good at putting people 
at their ease. (Isaac,40,UK)
Isaac’s quote highlights the importance of having non-judgemental professionals and this 
leads into the fourth theme of stigma. 
Theme 4: stigmatisation of AAS use
Several participants had experienced stigma, mainly at the hands of professionals:
I had a falling out with my one doctor …I was always open and honest … And instead 
of … talking to me about it, … he would more, more or less berate me about it, you 
know, so, I never felt that if I did have a problem…, I would have been able to bring it 
to him comfortably. (Lewis,37,USA)
Moreover, it was clear that this was a subject discussed openly amongst users who shared 
stories. This then influenced people who had no negative personal experiences:  
the experiences my sort of friends and team-mates have had, with healthcare 
professionals have been, … entirely negative… I feel like going to a healthcare 
professional with anything you know would be a last resort. (Alvin,36,UK)
Others talked about stigma in relation to using NSPs. They felt these services stigmatised 
them by classing them in the same group as other substances users who used dependence-
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inducing drugs such as opiates, often themselves reflecting societies’ stigma of such people 
referring to them as ‘junkies’, and as a result often chose not to use such services. 
Theme 5: paying for support services
The fifth theme was a clear willingness to pay for support services, although this was 
caveated that the cost would need to be reasonable. Many purchased their AAS-use 
paraphernalia online (and preferred doing so), paid to get blood-tests done privately and one 
even made it clear he used to donate whenever he got needles from an NSP. One participant 
felt that although it would be good to have free bloodwork that this might make people's 
decision to start using an easier one and felt therefore that payment for bloodwork was an 
important part of the decision-making process. Another saw AAS use as his choice, and 
therefore managing the side-effects were his responsibility, and should be at his own cost: 
it is my choice to take these steroids … it's my responsibility, it’s my body…morally I 
don't think it's right for me to put that demand on the NHS. (Peter,24,UK)
Theme 6: legality of AAS use – a change in the law
The legal status of AAS impacted on support in relation to harm minimisation as people were 
using them anyway. Some felt that if AAS use was legalised, people would feel more able to 
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seek advice from medical professionals and be able to buy from pharmacies which would 
reduce risk, as products would be of a good quality and not adulterated:
I would like to see it legalized so there would be like a standard, for example because 
I know a lot of people have fucked themselves up using somebody’s homebrew that 
they gave them infections. (Lewis,37,USA)
Your advice and your support and your sources and your education is driven 
underground and that is a problem. (Peter,24,UK)
It is worth noting that AAS users may have an ulterior motive in that by using AAS they may 
put themselves on the wrong side of the law. Moreover, not all participants agreed and one 
suggested that AAS should not be legalised:
I just think there should be a way where it can remain, I guess banned to the public 
but at least allow there to be clinical trials and moderated usage of it under the 
supervision of a health professionals (Paul,29,USA)
It was acknowledged that the legal situation affects public health polices, and here it was 
clear that few felt that the policies in place provided the necessary support for people who use 
AAS. The idea that people’s experiences were unique and could not be applied generically to 
use was referenced throughout the interviews. One participant summed up individualisation 
as a need to understand the motivations and circumstances of the individual:
when we talk about anabolic steroids, I think we have to say, ‘in what context, by 
whom and from whom, and for what purpose, … and under what circumstances?’ 
…We need to get the right on a policy level, we need to get the right kind of help, for 
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Many of the wishes for support services in this study are aligned to some of the services 
already supplied in a range of western countries, and others have been recommended by 
previous studies e.g. need for PCT advice (Griffiths, Henshaw, et al., 2016), and specialised 
harm reduction interventions for AAS users (Kimergård & McVeigh, 2014). A number of 
concerns raised in this paper have been previously raised in the literature including: risks of 
self-phlebotomy (Brennan, Wells, & Van Hout, 2018), stigma from health professionals 
(Griffiths, Murray, & Mond, 2016; Simmonds & Coomber, 2009), a risk of poor quality 
substances (Abbate et al., 2015; Cho et al., 2015; Coomber et al., 2014). The current public 
health focusing on harm minimisation treats AAS users as ‘another drug user’ which could be 
another reason as to why AAS users prefer to avoid public health services. This study echoes 
previous studies highlighting that AAS users are reluctant to engage with health services 
(Zahnow, McVeigh, Ferris, & Winstock, 2017) but wish to do so. Desires such as to discuss 
the effects of use with medical professionals; to see more research-led studies and evidenced-
based advice, alongside the willingness to pay for services potentially does set them apart 
from the more traditional users of such services. This desire for evidence-based advice is not 
surprising as this population has a high level of ethnopharmacological knowledge 
(Monaghan, 2002). This also goes someway to explain why participants were advocating for 
more human-based scientific research. 
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The public health focus on BBV risk aligned to AAS use is not something that the 
participants recognised, which raises the question why this focus? Participants talked about 
accessing NSPs and receiving information and needles; however, participants also spoke of 
stigma attached to this. Moreover, AAS users’ practices when injecting differ from those who 
inject illicit substances (e.g. heroin); the former tend to use swabs, do not share needles or 
vials and rarely re-use needles (Underwood, 2019). The majority of harm minimisation 
advice tends to be through NSPs and van de Ven and colleagues (2019) argue that this may 
miss an entire group of people who only use AAS orally. It could be argued that those 
working in this field, know that they are only likely to be funded if the focus is on wider 
public health issues i.e. BBV prevention, however, this is not helpful, if that very focus then 
is a barrier for some people accessing the service, and in this study less than half of the UK 
participants had accessed NSPs. 
Support services
Based on the wishes of the participants from this study the authors have outlined the services 
that it might be useful for a specialised steroid clinic to provide in order to meet the wide 
range of potential needs for people who use AAS (Figure 3). 
Figure 3 near here
This study highlights that first and foremost AAS users wanted medical support for side-
effects and previous studies have shown that access to medical examinations can help AAS 
users feel safer (Kimergård & McVeigh, 2014) and consequently it is worth including this 
provision as part of any specialised steroid service. Another potentially useful addition would 
be access to advice on nutrition and exercises, as some participants acknowledged that they 
started too young, and with the right advice on diet and exercise may not have started using 
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AAS so early. Furthermore, offering courses or sessions in mindfulness and meditation might 
be beneficial as some participants stated they already used such techniques to manage some 
of the emotional side-effects. Users wanted professionals to have personal experience, which 
is an unrealistic expectation; however, such wishes could in part be met by the setting up of 
peer-support groups. Services could require service users to make a donation, as this could 
provide services with a way of funding potential outreach services e.g. peer-led needle 
distribution (Kimergård & McVeigh, 2014), reduce stigma, and align with their value of 
taking responsibility for their use.  
Considering the recommendations for steroid clinic services (Figure 3), potentially the most 
controversial of these could be offering testing for quality of substance. However, evidence 
shows that much of the AAS sold is adulterated (Coomber et al., 2014) and testing of illicit 
recreational drugs is now part of many modern harm minimisation strategies (Brunt, 2017). 
AAS users were understandably concerned about drug quality and some even paid for testing 
through online companies as part of their personal harm minimisation strategy. This study 
also found evidence of AAS users not only wishing to give blood as a harm minimisation 
technique but also using blood donor services, and not disclosing their AAS use. Self-
phlebotomy is something that health professionals need to be aware of (Brennan et al., 2018), 
but it is also relevant to note there could be risks from public blood donation too. 
Interventions should be targeted at people who use AAS to improve their health outcomes 
(Bates et al., 2018) and the majority of interviewees supported this perspective, feeling that a 
focus on stopping use was not only unhelpful but also unrealistic. This is relevant as users 
noted that stopping use would not be possible due to their concerns about the negative effects 
of having low testosterone levels (due to age or AAS-use). The concerns around low 
testosterone causing depression and impacting on quality of life, appear to be one area within 
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this sub-community that deserves further attention. It is important for medical professionals 
to be well informed about IPED use not just to support physical health issues but also those 
experiencing low mood when off-cycle (Griffiths, Henshaw, et al., 2016). The idea that 
medical practitioners are not taking the impact of low mood among men seriously regardless 
of the cause is relevant because research suggests that there is a disparity with diagnosis of 
depression in gender, with medical practitioners less likely to diagnose depression in men 
(Salk, Hyde, & Abramson, 2017). The time is right to focus support services on psycho-social 
aspects of use as there is a wider societal movement to de-stigmatise mental health issues for 
men. Thus, further research into the emotional experiences coming off-cycle and behavioural 
changes such as increased irritation or anger, and loss of empathy when on cycle would be 
useful to inform the provision of effective support services. 
Timing of intervention is important and it is key to consider transitions in people’s lives 
(Bates et al., 2018), such as reaching an age where testosterone levels fall naturally or 
deciding to change your body shape and/or joining communities where AAS use is 
normalised. This supports participants’ calls for credible youth intervention, understanding 
that saying no is unrealistic. Any intervention needs to be tied to motivation (Boardley, Grix, 
& Dewar, 2014) and this study found that there was a notion that users wanted to be 
understood in relation to their personal motivations for use. Therefore, the authors suggest a 
need for further research into how motivations for use might impact on the type of support 
AAS users want across the lifespan.
Mechanisms of communication
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In relation to the provision of information and support, the ‘one-stop-shop’ service suggested 
could be an answer but does not address all the issues raised (possibly due to funding or 
policy issues). To do that it would need to be provided in conjunction with a range of other 
services via other sources, such as the online communities. Improving the provision of 
information through modern media is important to prevent harms and reduce the influence of 
those with vested interests (e.g. suppliers) (McVeigh, Evans-Brown, & Bellis, 2012) and 
using social media and online networking has been recommended (Glass, Hope et al. 2019). 
The authors add their voice to many before us (Bates et al., 2018; Glass et al., 2019; Griffiths, 
Henshaw, et al., 2016; Kimergård & McVeigh, 2014; Salinas et al., 2019; Underwood, 2019; 
van de Ven et al., 2019) who are advocating for a review of public health initiatives with a 
view that they look to utilise more innovative methods of dissemination via peer networks. 
Underwood (2019) advocates engaging the experienced users, the social influencers, to 
promote harm-reduction services, and reminds us that when we publish research on AAS we 
are often speaking directly to the community, as users seek out evidence-based knowledge 
and this was clearly evidenced in our interviews. Furthermore, it was not just the channels 
that were seen as important, but that the advice was balanced. Previous studies have 
advocated the need for professionals to acknowledge the efficacy of steroids (Griffiths, 
Murray, Mitchison, & Mond, 2016) and this was something that was desired and a more 
individualised approach is needed ‘based on thorough assessment of risk behavior, lifestyle 
and underlying health’ (Zahnow et al., 2018, p111). Our interviews highlight the broader 
necessity to reconsider the current support approaches, moving away from conversations 
about needle sharing and stopping use; to conversations about wider long-term harm 
minimisation and practical advice including ‘how to inject’. In this study most participants 
were self-taught and used online instructions or videos to support this. There are videos by 
professionals on safer injecting (Public Health Wales, 2019). Perhaps increasing the publicity 
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of such resources and involving experienced users in such initiatives might help ensure that 
the ‘right’ information is being shared to help people minimise risks, with NSPs also offering 
this guidance. 
Removing barriers
Removing barriers to access is key. The AAS users readily shares information and stories, 
and therefore if one person has a poor experience with a professional that this is shared 
widely within the community. Professionals need to be aware of both this network and also 
acknowledge how harmful their judgements can be with regards to people accessing support. 
What is surprising around the concept of medical professionals needing to be both credible 
and non-judgemental is that this information has been available in the academic literature for 
a long-time (Grogan, Shepherd, Evans, Wright, & Hunter, 2006; Simmonds & Coomber, 
2009). This raises the question of what more needs to be done by the academic community to 
help encourage the academic evidence to be incorporated into policies and practice.
Identity as an AAS user
One central idea integral to each of the six individual themes identified, is identity. It is clear 
from this study that AAS users do not identify themselves as ‘illicit drug-users’ in the sense 
they clearly want to distance themselves from people who are dependent on heroin or 
cocaine, which echoes the findings of other studies (McVeigh et al., 2012), and although 
there is evidence of poly-drug use within this community (Begley, McVeigh, & Hope, 2017; 
Cornford, Kean, & Nash, 2014), only one interviewee talked of using any other illicit drugs 
and participants were clear that they saw their use as different to that of other users. 
Moreover, some of those who saw their use as TRT, no longer saw themselves as AAS users 
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but instead just saw it as a form of self-prescribed medication. There is a need to develop 
‘better understandings of the health and wellbeing issues’ for AAS users in order to ‘design 
more credible and engaging policy responses’ (Moore, Hart, Fraser, & Seear, 2019, p15) and 
with the ‘one-size-fits-all’ attitude of public health information literature being inadequate, as 
it does not acknowledge the diversity of people who use AAS (Underwood, 2019). 
Strengths and limitations
To our knowledge this is the first study to directly ask AAS users about the ideal types of 
information and support they want. This study may not represent all types of AAS users; 
however, there were similarities found across geographical regions and the age ranges 
suggests a level of diversity and consequently sheds light on the types of information and 
support wanted. Participants may have under-reported the severity of side-effects or need for 
support because of shame or fear that such studies may mean an increase in attention from 
authorities into steroid use, which could negatively influence the legal situation. This study 
acknowledges that there may be geographical/legal differences dependent on country of 
residence. The study also did not look at the specific information and support needed for each 
of the different substances and associated brands, however, it did find that one AAS, namely 
Trenbolone, was referenced as having problematic side-effects and this is a potential area for 
further research. This study also recommends that specialised steroid clinics are potentially a 
good way of providing support to AAS users, however in line with previous studies 
(Kimergård & McVeigh, 2014; Tighe et al., 2017), a limitation is the lack of evidence-base 
concerning the impact of such services (often due to policy changes or funding limitations on 
such services) and therefore there is a need for evaluation of the effectiveness of such 
services particularly aligned to harm minimisation for this population. 
Conclusion
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There is a need to encourage professionals to share good practice not only with other 
professionals but more widely within the AAS community and we advocate that any 
approach be person-centred. Moreover, governments need to take note of the wealth of 
building evidence for such a personalised approach within both the AAS user and academic 
communities. We would advocate that professionals continue to take a harm minimisation 
approach and investigate ways to engage influencers within the community with harm 
minimisation activities, as well as try to measure the impact of any specialised AAS services. 
We advocate for more consideration being given to the types of support for men who are 
experiencing depressive symptoms and those with psychological complications surrounding 
AAS use. We support the development of specialized steroid services as part of public health 
initiatives and suggest they consider ways for AAS users to give voluntary donations or be 
charged a nominal fee for specialist harm minimisation paraphernalia. Emphasis needs to be 
placed on ensuring services are delivered by knowledgeable, non-judgemental professionals 
who take a neutral view of AAS use and understand the complex motivations for use and the 
benefits. 
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Figure 1: Themes: information and support wanted by AAS users
Figure 2: Mechanisms for communication
Figure 3. Suggested services for specialist IPED/AAS Clinics
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Table 1– Demographics of Participants 






Highest level of 
education 
Employed
Clinton UK 20 Male College/University Employed/Student
Peter UK 24 Male College/University Student
Andrew UK 25 Male College/University Student
Lawrie UK 27 Male College/University Employed/Student
Asi USA 28 Male College/University Employed
Paul USA 29 Male College/University Employed
Theo Denmark 30 Male College/University Student
Lev Canada 32 Male College/University Employed
Powel USA 34 Male College/University Student
Joel USA 34 Male Primary/Secondary Employed
Robert Spain 34 Male College/University Employed
Del UK 35 Male College/University Employed
Alvin UK 36 Male College/University Student
Johan Hong Kong 36 Male College/University Employed
Lewis USA 37 Male College/University Employed
Don UK 39 GF College/University Student
Milton UK 40 Male Primary/Secondary Retired
Tomaz Belgium 40 Male College/University Employed
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Isaac UK 42 Male College/University Student
Han UK 42 Male Primary/Secondary Other
Lee USA 43 Male College/University Employed
Harry UK 52 Male College/University Employed
Hugo USA 53 Male College/University Student
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Appendix 1 
Self-reported effects of using Trenbolone
This study did not seek to find out the individual effects of specific brands or types of AAS 
however, one substance ‘Trenbolone’ did stand out as something that could have very 
beneficial effects but was also particularly problematic to use, in relation to unwanted 
behavioural side effects.
Use Quote
‘compounds cause behavioural changes like Trenbolone so I no longer use that steroid’ 
(Nick/USA/50)
‘Tren has caused heightened aggression. If estrogen [sic] spikes I can get moody but knowing 
my dosages and blood levels I can actually manage moods more’ (Rod/Australia/39)
‘Trenbolone makes me very short tempered, aggressive and my mind is filled with viscious 
[sic] and violent thoughts’ (Don/UK/39)
‘that is the one compound that does make me raise an eyebrow, but just because of the people 
that have come back to me after using it, and said, that I can’t ever use that again, I went crazy’  
(Robert/Spain/34)
‘I never got on with Trenbolone. Trenbolone was one steroid that did make me irritable and did 
make me agitated.’ (Isaac/UK/42)
‘I did use one compound: trenbolone, for a while and I had every negative side effect with it 
imaginable with that; I had shortness of breath, I had flushing, I had night sweats, I had quick, 
quick to enrage.’ (Hugo/USA/53)
it made me so indifferent about like my relationship with the people around me. It's like it was 
almost like a sense of arrogance that no one else really mattered around me’ (Peter/UK/24)
‘I'm running Tren right now, and you know I get the full nightmares, I get the extreme sweats, 
the insomnia is pretty bad... I don't forget a single bit of the, the terror of the nightmare.’ 
(Lewis/USA/37)
‘Tren is not the best drug to take, …I am not emotional but Tren’s not a good drug if you are 
not very in control of your impulses and your emotions and I am on Tren right now but very 
small doses of it because I've taken it before, and like man it just, it just makes you so 
depressed for no reason... I'm terrified of getting fat again... so that's why I like doing Tren so 
much, because it, it just sucks everything down really well …I don't know if I'm gonna keep 
doing it because …I'm not empathetic to stuff... I don't like the person that I am, when I'm 
doing it.’ (Joel/USA/34)
‘I am on trenbolone and that could cause, actually that could cause problems right now. 
Definitely it's easier to get angry and Yeah, lose control that’s for sure. Especially on 
trenbolone because that's a very specific compound, lots of friends and guys at the gym would 
say the same thing’ (Lev/Canada/32)
‘I used it for a period of around eight weeks and I didn't get any sort of heightened aggression 
which some people find I didn't you know I got night sweats, it reduced the amount of sleep I 
needed it seemed and but it made me so indifferent about like my relationship with the people 
around me. It's like it was almost like a sense of arrogance that no one else really mattered 
around me’ (Peter,24,UK)
‘I am having occasionally light night sweats, occasionally, slight er acid reflux, but no problem 
at all. It is very easy…um, with the Tren, I noticed initially a slight increase in irritability when 
I am driving, so you know, swearing at other drivers, you know, in my head sometimes, but 
that has passed now’ (Del,35,UK)
Effects on 
Cycle 
‘Very low mood after using trenabol’ (Grant/UK/29)
After a Cycle ‘First cycle, off Tren I was very insecure’ (Jason/UK/40)
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